155 related articles for article (PubMed ID: 11060749)
1. An update on satraplatin: the first orally available platinum anticancer drug.
Kelland LR
Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
[TBL] [Abstract][Full Text] [Related]
2. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
3. Satraplatin: an orally available platinum analog for the treatment of cancer.
Choy H
Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
[TBL] [Abstract][Full Text] [Related]
4. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
[TBL] [Abstract][Full Text] [Related]
6. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
McKeage MJ
Drugs; 2007; 67(6):859-69. PubMed ID: 17428104
[TBL] [Abstract][Full Text] [Related]
7. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
12. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
13. Rapid biotransformation of satraplatin by human red blood cells in vitro.
Carr JL; Tingle MD; McKeage MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):9-15. PubMed ID: 12111106
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
15. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
16. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
17. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
Kelland L
Expert Opin Investig Drugs; 2007 Jul; 16(7):1009-21. PubMed ID: 17594186
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pharmacokinetic evaluation of satraplatin.
Doshi G; Sonpavde G; Sternberg CN
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):103-11. PubMed ID: 22098065
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
